Evidence map›Paper›PMID 30206160›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.

Kathy Matuszewska, Lisa A Santry, Jacob P van Vloten, Amanda W K AuYeung, Pierre P Major, Jack Lawler, Sarah K Wootton, Byram W Bridle, Jim Petrik

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. The biological roles of CD47 in ovarian cancer progression.Cancer immunology, immunotherapy : CII · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Kathy Matuszewska *Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.ORCID 0000-0002-7269-8538
Lisa A Santry *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Jacob P van Vloten *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.ORCID 0000-0002-3752-9499
Amanda W K AuYeung *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Pierre P MajorDepartment of Oncology, McMaster University, Hamilton, Ontario, Canada.
Jack LawlerDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Sarah K Wootton *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
Byram W Bridle *Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.ORCID 0000-0002-8335-1118
Jim PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada. jpetrik@uoguelph.ca.
University of Guelph · CABeth Israel Deaconess Medical Center · USMcMaster University · CA

Funding

CIHR
6 · The paper itself

Abstract

purposeIntravenous delivery of oncolytic viruses often leads to tumor vascular shutdown, resulting in decreased tumor perfusion and elevated tumor hypoxia. We hypothesized that using 3TSR to normalize tumor vasculature prior to administration of an oncolytic Newcastle disease virus (NDV) would enhance virus delivery and trafficking of immunologic cell subsets to the tumor core, resulting in systemically enhanced immunotherapy and regression of advanced-stage epithelial ovarian cancer (EOC). EXPERIMENTAL

designUsing an orthotopic, syngeneic mouse model of advanced-stage EOC, we pretreated mice with 3TSR (4 mg/kg per day) alone or followed by combination with fusogenic NDV(F3aa) (1.0 × 10

resultsTreatment with 3TSR normalized tumor vasculature, enhanced blood perfusion of primary EOC tumors, and induced disease regression. Animals treated with combination therapy had the greatest reduction in primary tumor mass, ascites accumulation, and secondary lesions (50% of mice were completely devoid of peritoneal metastases). Combining 3TSR + NDV(F3aa) led to enhanced trafficking of immunologic cells into the primary tumor core.

conclusionsWe have shown, for the first time, that NDV, like other oncolytic viruses, is a potent mediator of acute vascular shutdown and that preventing this through vascular normalization can promote regression in a preclinical model of advanced-stage ovarian cancer. This challenges the current focus on induction of intravascular thrombosis as a requisite for successful oncolytic virotherapy.

Indexed as

Genetic VectorsNeovascularization, PathologicOncolytic VirotherapyOncolytic VirusesAngiogenesis InhibitorsAnimalsCell Line, TumorCell SurvivalCombined Modality TherapyCytokinesDisease Models, AnimalFemaleHumansHypoxiaImmunomodulationInterferonsAngiogenesis InhibitorsCytokinesInterferons

Identifiers

PMID30206160
OpenAlexW2909211125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.